Choice of Oral Presentations
Joaquin Mateo, Nuria Porta, Ursula Brigid McGovern, Tony Elliott, et al.
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.
Conclusions: Olaparib has antitumor activity against heavily pre-treated mCRPC with DDR gene defects, with BRCA1/2 aberrant tumors being most sensitive but with confirmed responses in patients with other DDR alterations. Clinical trial information: NCT01682772
Kim N. Chi, Neeraj Agarwal, Anders Bjartell, Byung Ha Chung, et al.
First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
Conclusions: In the TITAN study in pts with mCSPC, including pts with high- and low-volume disease and prior docetaxel, addition of APA to ADT significantly improved rPFS and OS, and the safety profile was tolerable. These results support the addition of APA to ADT for tx of pts with mCSPC. Clinical trial information: NCT02489318
Michael J. Morris, Glenn Heller, Alan Haruo Bryce, Andrew J. Armstrong, et al.
Metastatic Renal Cell Carcinoma
Metastatic Urothelial Cancer
Conclusions: Switch maintenance pembro may “deepen” responses achieved with 1st-line chemotherapy. Switch maintenance pembro prolongs PFS in pts with mUC completing 1st-line platinum-based chemotherapy. Clinical trial information: NCT02500121
|Placebo (N=52)||Pembro (N=55)|
|Age, median (range)||65 (44-87)||68 (41-83)|
|Pre-chemo metastatic disease|
|Visceral metastases||32 (62%)||39 (71%)|
|No visceral metastases||20 (38%)||16 (29%)|
|Median # cycles of 1st line chemo||6||5|
|Response to 1st line chemotherapy|
|CR/PR||36 (69%)||40 (73%)|
|SD||16 (31%)||15 (27%)|
|1st line chemo|
|Carboplatin-based||11 (21%)||16 (29%)|
|Cisplatin-based||41 (79%)||39 (71%)|
Clinical Science Symposium
Toni K. Choueiri, Laurence Albiges, John B. A. G. Haanen, James M.G. Larkin, et al.
Conclusions: These findings define molecular features that differentiate therapy-specific outcomes in first-line aRCC and may inform personalized therapy strategies for pts with aRCC. Funding: Pfizer and Merck KGaA. Clinical trial information: NCT02684006 https://clinicaltrials.gov/ct2/show/NCT02684006